Literature DB >> 23312933

Contraceptive vaginal ring effectiveness is maintained during 6 weeks of use: a prospective study of normal BMI and obese women.

Monica Dragoman1, Kelsey Petrie, Anupama Torgal, Tiffany Thomas, Serge Cremers, Carolyn L Westhoff.   

Abstract

BACKGROUND: A single study shows that contraceptive vaginal ring (CVR) use for up to 35 days in women with a normal body mass index (BMI) maintains serum hormone levels sufficient to suppress ovulation. This study is intended to confirm those results and to evaluate prolonged CVR use up to 42 days in both normal BMI and obese women. STUDY
DESIGN: Twenty women with a normal BMI and 20 obese women enrolled in a prospective open label clinical study of ethinyl estradiol (EE) and etonogestrel (ENG) pharmacokinetics during six weeks of use of a single CVR. Participants underwent twice-weekly evaluations to determine serum hormone concentrations, ovarian follicle development, endometrial thickness and bleeding patterns.
RESULTS: Thirty-seven women completed follow-up including eighteen women with a normal BMI and nineteen obese women. EE and ENG concentrations remained in therapeutic range for all women. Follicular development and endometrial proliferation were minimal. By the sixth week, 30% of participants reported spotting or bleeding.
CONCLUSIONS: A single CVR used for 6 weeks demonstrates therapeutic serum levels of EE and ENG among women with normal and obese BMI. Women who forget to remove the CVR at day 21 may well have continued contraceptive protection during the next 3 weeks.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23312933      PMCID: PMC3606661          DOI: 10.1016/j.contraception.2012.12.001

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  13 in total

1.  Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition.

Authors:  T M Mulders; T O Dieben
Journal:  Fertil Steril       Date:  2001-05       Impact factor: 7.329

2.  Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring.

Authors:  C J Timmer; T M Mulders
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

3.  Pharmacokinetics and ovarian suppression during use of a contraceptive vaginal ring in normal-weight and obese women.

Authors:  Carolyn L Westhoff; Anupama H Torgal; Elizabeth Rose Mayeda; Kelsey Petrie; Tiffany Thomas; Monica Dragoman; Serge Cremers
Journal:  Am J Obstet Gynecol       Date:  2012-04-28       Impact factor: 8.661

4.  Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone.

Authors:  Hans-Joachim Ahrendt; Israel Nisand; Carlo Bastianelli; Maria Angeles Gómez; Kristina Gemzell-Danielsson; Wolfgang Urdl; Birgit Karskov; Luc Oeyen; Johannes Bitzer; Geert Page; Ian Milsom
Journal:  Contraception       Date:  2006-09-27       Impact factor: 3.375

5.  The combined contraceptive vaginal ring (NuvaRing): first experience in daily clinical practice in The Netherlands.

Authors:  Frans J M E Roumen; Monique M T op ten Berg; Eric H M Hoomans
Journal:  Eur J Contracept Reprod Health Care       Date:  2006-03       Impact factor: 1.848

Review 6.  The pharmacokinetics and pharmacodynamics of Implanon, a single-rod etonogestrel contraceptive implant.

Authors:  H J Bennink
Journal:  Eur J Contracept Reprod Health Care       Date:  2000-09       Impact factor: 1.848

7.  Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial.

Authors:  Kristjan Oddsson; Beate Leifels-Fischer; Nilson Roberto de Melo; Dominique Wiel-Masson; Chiara Benedetto; Carole H J Verhoeven; Thom O M Dieben
Journal:  Contraception       Date:  2005-03       Impact factor: 3.375

8.  Clinical results with subcutaneous implants containing 3-keto desogestrel.

Authors:  S E Olsson; V Odlind; E Johansson
Journal:  Contraception       Date:  1990-07       Impact factor: 3.375

9.  Improving contraceptive use in the United States.

Authors:  Jennifer J Frost; Jacqueline E Darroch; Lisa Remez
Journal:  Issues Brief (Alan Guttmacher Inst)       Date:  2008

10.  Clinical trial with 3-keto-desogestrel subdermal implants.

Authors:  S Díaz; M Pavez; A J Moo-Young; C W Bardin; H B Croxatto
Journal:  Contraception       Date:  1991-10       Impact factor: 3.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.